{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:29:47Z","timestamp":1789241387600,"version":"build-2803163510"},"reference-count":47,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.jim.2011.12.002","type":"journal-article","created":{"date-parts":[[2011,12,17]],"date-time":"2011-12-17T05:12:46Z","timestamp":1324098766000},"page":"97-107","source":"Crossref","is-referenced-by-count":49,"title":["Validation and long term performance characteristics of a quantitative enzyme linked immunosorbent assay (ELISA) for human anti-PA IgG"],"prefix":"10.1016","volume":"376","author":[{"given":"V.A.","family":"Semenova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Steward-Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Soroka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.M.","family":"Brawner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2011.12.002_bb0005","doi-asserted-by":"crossref","first-page":"6740","DOI":"10.1016\/j.vaccine.2010.07.075","article-title":"An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor","volume":"28","author":"Baillie","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0010","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.vaccine.2004.10.014","article-title":"Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants","volume":"23","author":"Berthold","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0015","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1016\/j.vaccine.2007.05.043","article-title":"Detection of anti-protective antigen salivary IgG antibodies in recipients of the US licensed anthrax vaccine","volume":"25","author":"Bienek","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0020","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1128\/CVI.00473-07","article-title":"Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccine","volume":"15","author":"Bienek","year":"2008","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.jim.2011.12.002_bb0025","series-title":"An Assessment of the CDC Anthrax Vaccine Safety and Efficacy Research Program","author":"Committee to Review the CDC Anthrax Vaccine Safety and Efficacy Research Program","year":"2002"},{"key":"10.1016\/j.jim.2011.12.002_bb0030","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3201\/eid0810.020330","article-title":"Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001","volume":"8","author":"Dewan","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jim.2011.12.002_bb0040","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1016\/S0264-410X(01)00021-4","article-title":"Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin","volume":"19","author":"Fellows","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0045","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/S0264-410X(01)00461-3","article-title":"Anthrax vaccine efficacy in golden Syrian hamsters","volume":"20","author":"Fellows","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0050","author":"Food and Drug Administration"},{"key":"10.1016\/j.jim.2011.12.002_bb0060","author":"Food and Drug Administration"},{"key":"10.1016\/j.jim.2011.12.002_bb0065","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7589\/0090-3558-44.3.721","article-title":"Naturally acquired anthrax antibodies in a cheetah (Acinonyx jubatus) in Botswana","volume":"44","author":"Good","year":"2008","journal-title":"J. Wildl. Dis."},{"key":"10.1016\/j.jim.2011.12.002_bb0070","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1016\/j.vaccine.2006.05.044","article-title":"Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, placebo controlled, multicenter trial","volume":"24","author":"Gorse","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0889-8561(03)00093-6","article-title":"Anthrax vaccine: a review","volume":"23","author":"Grabenstein","year":"2003","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.jim.2011.12.002_bb0080","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1016\/j.vaccine.2007.01.056","article-title":"Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine","volume":"25","author":"Grunow","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0085","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/15321810701454706","article-title":"Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine","volume":"28","author":"Gubbins","year":"2007","journal-title":"J. Immunoassay Immunochem."},{"key":"10.1016\/j.jim.2011.12.002_bb0090","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3201\/eid0810.020332","article-title":"Opening a Bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response","volume":"8","author":"Hsu","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jim.2011.12.002_bb0095","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1128\/IAI.00368-09","article-title":"The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example","volume":"77","author":"Hughes","year":"2009","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jim.2011.12.002_bb0100","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S0264-410X(98)80112-6","article-title":"Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques","volume":"16","author":"Ivins","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0105","series-title":"The Anthrax Vaccine: Is it Safe? Does It Work","year":"2002"},{"key":"10.1016\/j.jim.2011.12.002_bb0255","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2011.12.002_bb0115","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.vaccine.2006.11.005","article-title":"The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine","volume":"25","author":"Lininger","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0120","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1016\/j.vaccine.2005.12.028","article-title":"Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine","volume":"24","author":"Little","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0125","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1016\/j.vaccine.2010.04.094","article-title":"Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads","volume":"23","author":"Madore","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0130","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effect of a reduced dose schedule and intramuscular administration of Anthrax Vaccine Adsorbed on immunogenicity and safety at 7 months: a randomized trial","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jim.2011.12.002_bb0135","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/clinchem\/46.1.100","article-title":"General deming regression for estimating systematic bias and its confidence interval in method-comparison studies","volume":"46","author":"Martin","year":"2000","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jim.2011.12.002_bb0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0169-7439(93)80008-6","article-title":"Calibration and assay development using the four-parameter logistic model","volume":"20","author":"O'Connell","year":"1993","journal-title":"Chemom. Intell. Lab. Syst."},{"key":"10.1016\/j.jim.2011.12.002_bb0145","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0264-410X(00)00174-2","article-title":"Anthrax vaccine: increasing intervals between the first two doses enhances antibody response in humans","volume":"15","author":"Pittman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0150","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0155","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/CDLI.12.6.713-721.2005","article-title":"Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis","volume":"12","author":"Pittman","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.jim.2011.12.002_bb0160","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/JCM.32.10.2441-2447.1994","article-title":"Determination of parallelism and nonparallelism in bioassay dilution curves","volume":"32","author":"Plikaytis","year":"1994","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jim.2011.12.002_bb0165","unstructured":"Plikaytis, B.D, Carlone, G.M., Program ELISA for Windows User's Manual, version 2. Centers for Disease Control and Prevention, Atlanta, GA, U.S.A., 2005. Please add the link: http:\/\/www.cdc.gov\/ncidod\/dbmd\/bimb\/elisa.htm"},{"key":"10.1016\/j.jim.2011.12.002_bb0170","series-title":"44th Intersci. Conf. Antimicrob Agents Chemother. abstr. D-1376","article-title":"Inter-laboratory Evaluation of an Anti-PA IgG ELISA Abstr","author":"Purvis","year":"2004"},{"key":"10.1016\/j.jim.2011.12.002_bb0175","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1128\/JB.85.1.230-236.1963","article-title":"Gel Adsorbed Protective Antigen for Immunization of Man","volume":"85","author":"Puziss","year":"1963","journal-title":"J. Bacteriol."},{"key":"10.1016\/j.jim.2011.12.002_bb0185","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human Immunoglobulin G antibodies to anthrax protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jim.2011.12.002_bb0190","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1086\/423937","article-title":"Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax","volume":"190","author":"Quinn","year":"2004","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jim.2011.12.002_bb0195","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CDLI.11.5.919-923.2004","article-title":"Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum","volume":"11","author":"Semenova","year":"2004","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"10.1016\/j.jim.2011.12.002_bb0200","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.vaccine.2006.11.028","article-title":"Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax","volume":"25","author":"Semenova","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0205","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1016\/j.vaccine.2007.05.003","article-title":"Evaluation of immune response to orally administered Sterne strain 34F2 anthrax vaccine","volume":"25","author":"Shakya","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0210","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.vaccine.2007.11.085","article-title":"Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel","volume":"26","author":"Singer","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.jim.2011.12.002_bb0215","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/0021-9797(88)90190-7","article-title":"Physiochemical and biochemical aspects of fibrinogen adsorption from plasma and binary proteins solutions onto polyethylene glass","volume":"124","author":"Slack","year":"1988","journal-title":"J. Colloid Interface Sci."},{"key":"10.1016\/j.jim.2011.12.002_bb0220","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1002\/jbm.820261208","article-title":"Changes in fibrinogen adsorbed to segmented polyurethanes and hydroxyethylmethacrylate-ethylmethacrylate copolymers","volume":"26","author":"Slack","year":"1992","journal-title":"J. Biomed. Mater. Res."},{"key":"10.1016\/j.jim.2011.12.002_bb0225","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.biologicals.2010.09.001","article-title":"A two-stage, multilevel quality control system for serological assays in anthrax vaccine clinical trials","volume":"38","author":"Soroka","year":"2010","journal-title":"Biologicals"},{"key":"10.1016\/j.jim.2011.12.002_bb0230","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1128\/IAI.52.2.356-363.1986","article-title":"Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity","volume":"52","author":"Turnbull","year":"1986","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jim.2011.12.002_bb0235","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4102\/ojvr.v75i2.6","article-title":"Naturally acquired antibodies to Bacillus anthracis protective antigen in vultures of southern Africa","volume":"75","author":"Turnbull","year":"2008","journal-title":"Onderstepoort J. Vet. Res."},{"key":"10.1016\/j.jim.2011.12.002_bb0240","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1086\/512372","article-title":"A case of naturally acquired inhalation anthrax clinical care and analysis of anti-protective antigen immunoglobulin G and lethal factor","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jim.2011.12.002_bb0245","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0882-4010(88)90015-0","article-title":"Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice","volume":"5","author":"Welkos","year":"1988","journal-title":"Microb. Pathog."},{"issue":"RR-6","key":"10.1016\/j.jim.2011.12.002_bb0250","first-page":"1","article-title":"Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"MMWR Recomm. Rep."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217591100319X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002217591100319X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T23:15:06Z","timestamp":1593386106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002217591100319X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":47,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S002217591100319X"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2011.12.002","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}